Skip to main content
. 2021 Jun 24;39(26):2859–2871. doi: 10.1200/JCO.20.03060

FIG 3.

FIG 3.

TP53 mutations and association with survival. (A) KM analysis of EFS within the COG FN cohort (n = 275) by the presence of a TP53 Mut or absence of a TP53 lesion (TP53 WT). (B) KM analysis of EFS within the COG FN cohort by TP53 status and RMS risk category. Total case numbers: low, n = 124; intermediate, n = 126; high, n = 35. (C) KM analysis of EFS within the UK FN cohort (n = 240) by the presence of a TP53 Mut or absence of a TP53 lesion (TP53 WT). (D) KM analysis of EFS within the UK FN cohort by TP53 status and RMS risk category. Total case numbers: low, n = 96; intermediate, n = 113; high, n = 25. Presented P values are log-rank and BH adj. HR with 95% CI. BH adj, Benjamini-Hochberg–adjusted; COG, Children's Oncology Group; EFS, event-free survival; FN, fusion-negative; HR, hazard ratio; KM, Kaplan-Meier; RMS, rhabdomyosarcoma; TP53 Mut, TP53 mutation; TP53 WT, TP53 wild type.